PANX1 and COVID-19: Probenecid, a potent Panx-1 inhibitor, has proven to be a promising target of inflammation in different diseases (Beyer et al., 1995; Goodenough et al., 1996; Duffy et al., 2000), including COVID-19 pathogenesis, where Panx-1 mRNA expression was responsible for increased ATP and IL-1β levels in human lung epithelial cells infected with SARS-CoV-2.